Gilead Sciences Finally Starts Succeeding [Seeking Alpha]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Seeking Alpha
The company has struggled with acquisitions but is expected to generate strong shareholder returns. Gilead Sciences has new businesses and milestones planned for 2024. The Retirement Forum members get exclusive access to our real-world portfolio. See all our investments here » Gilead Sciences NASDAQ: GILD ) has been perhaps one of the most discussed biotech companies as an investment. The company effectively was the first to cure Hepatitis C, capitalizing on an incredibly strong HIV business, before competition hurt its market position substantially. Since then, the company has become known for massive acquisitions that have struggled to pan out. Despite that, it seems like the times are finally changing. The company is building an exciting new oncology business, and we expect it'll be able to drive substantial shareholder returns going forward. Gilead Sciences 2023 Results The company closed out with a fairly strong 2023, in relation to a market capitalization of just un
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Morgan Stanley from $80.00 to $78.00. They now have an "equal weight" rating on the stock.MarketBeat
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at TD Cowen from $90.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Royal Bank of Canada from $76.00 to $74.00. They now have a "sector perform" rating on the stock.MarketBeat
- Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat [Yahoo! Finance]Yahoo! Finance
- Merus (MRUS) Moves 7.1% Higher: Will This Strength Last? [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 4/26/24 - Form 4
- 4/25/24 - Form 8-K
- 4/2/24 - Form 4
- GILD's page on the SEC website